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IMPORTANCE Owing to a considerable shift toward bioprosthesis implantation rather than
mechanical valves, it is expected that patients will increasingly present with degenerated
bioprostheses in the next few years. Transcatheter aortic valve-in-valve implantation is a less
invasive approach for patients with structural valve deterioration; however, a comprehensive
evaluation of survival after the procedure has not yet been performed.
OBJECTIVE To determine the survival of patients after transcatheter valve-in-valve
implantation inside failed surgical bioprosthetic valves.
DESIGN, SETTING, AND PARTICIPANTS Correlates for survival were evaluated using a
multinational valve-in-valve registry that included 459 patients with degenerated
bioprosthetic valves undergoing valve-in-valve implantation between 2007 andMay 2013 in
55 centers (mean age, 77.6 [SD, 9.8] years; 56%men; median Society of Thoracic Surgeons
mortality prediction score, 9.8% [interquartile range, 7.7%-16%]). Surgical valves were
classified as small (21 mm; 29.7%), intermediate (>21 and <25mm; 39.3%), and large (25
mm; 31%). Implanted devices included both balloon- and self-expandable valves.
MAIN OUTCOMES ANDMEASURES Survival, stroke, and New York Heart Association functional
class.
RESULTS Modes of bioprosthesis failure were stenosis (n = 181 [39.4%]), regurgitation (n = 139
[30.3%]), and combined (n = 139 [30.3%]). The stenosis group had a higher percentage of
small valves (37% vs 20.9% and 26.6% in the regurgitation and combined groups,
respectively; P = .005). Within 1 month following valve-in-valve implantation, 35 (7.6%)
patients died, 8 (1.7%) hadmajor stroke, and 313 (92.6%) of surviving patients had good
functional status (New York Heart Association class I/II). The overall 1-year Kaplan-Meier
survival rate was 83.2% (95%CI, 80.8%-84.7%; 62 death events; 228 survivors). Patients in
the stenosis group hadworse 1-year survival (76.6%; 95%CI, 68.9%-83.1%; 34 deaths; 86
survivors) in comparisonwith the regurgitation group (91.2%; 95%CI, 85.7%-96.7%; 10
deaths; 76 survivors) and the combined group (83.9%; 95%CI, 76.8%-91%; 18 deaths; 66
survivors) (P = .01). Similarly, patients with small valves hadworse 1-year survival (74.8% [95%
CI, 66.2%-83.4%]; 27 deaths; 57 survivors) vs with intermediate-sized valves (81.8%; 95%CI,
75.3%-88.3%; 26 deaths; 92 survivors) andwith large valves (93.3%; 95%CI, 85.7%-96.7%; 7
deaths; 73 survivors) (P = .001). Factors associatedwithmortality within 1 year included
having small surgical bioprosthesis (21mm; hazard ratio, 2.04; 95%CI, 1.14-3.67; P = .02) and
baseline stenosis (vs regurgitation; hazard ratio, 3.07; 95%CI, 1.33-7.08; P = .008).
CONCLUSIONS AND RELEVANCE In this registry of patients who underwent transcatheter
valve-in-valve implantation for degenerated bioprosthetic aortic valves, overall 1-year survival
was 83.2%. Survival was lower among patients with small bioprostheses and those with
predominant surgical valve stenosis.
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S urgical aortic valve replacements increasingly use bio-prosthesis implants rather than mechanical valves.1Structural valve deterioration can result in leaflet
degeneration and failure, as evidenced by valve stenosis,
regurgitation, or a combination of both.2-4 Owing to a con-
siderable shift toward bioprosthesis implantation, it is
expected that patients will increasingly present with degen-
erated bioprostheses. Treatment of patients with failed bio-
prostheses is a clinical challenge. Although reoperation is
considered the standard of care, these patients are fre-
quently elderly, and repeat cardiac surgery carries significant
morbidity and mortality risks.5,6
Transcatheter aortic valve replacementhas becomeanal-
ternative, less invasive treatment for patients at high surgical
risk with severe symptomatic native aortic valve stenosis.7-11
Previous reports have demonstrated the feasibility of treat-
ingdegeneratedbioprostheseswith transcatheterheart valves
inside failed surgical valves (eFigure 1 in the Supplement).12-16
Preliminary data from the Valve-in-Valve International Data
(VIVID)Registry revealed thatalthoughprocedural successwas
achieved in93.1%ofpatients, thevalve-in-valveprocedure in-
cludedseveral safetyandefficacyconcerns.17However, a com-
prehensive long-term evaluation of valve-in-valve proce-
duresof a larger groupofpatientswith considerable follow-up
has not yet been performed.
Methods
Registry Design
The VIVID Registry was initiated in December 2010 and was
designed to collect data on valve-in-valve procedures using
mainly self-expandable CoreValve (Medtronic) and balloon-
expandableEdwards SAPIENdevices (Edwards Lifesciences).
Valve-in-valve procedures performed using other transcath-
eter devices or implanted in positions other than the aortic
valvewere not included in the current analyses.We collected
data retrospectively for cases performed before registry ini-
tiation andprospectively thereafter. A total of 55 centers from
Europe,NorthAmerica,Australia,NewZealand,andtheMiddle
East contributeddata (eTable 1 in the Supplement). Datawere
collectedforcasesperformedbetween2007andMay2013using
a dedicated case report form. All inconsistencies were re-
solveddirectlywith local investigators andon-site datamoni-
toring. All patients gave written informed consent to a trans-
catheter aortic valve-in-valve procedure. The inclusion of
patients was approved in each center by a local ethics com-
mittee.
Definitions
Prediction of patient operative mortality after conventional
surgical valve replacement was calculated using the Society
of Thoracic Surgeons (STS) score (http://riskcalc.sts.org
/de.aspx) and the LogEuroSCORE (http://www.euroscore
.org/calcold.html). Mechanism of bioprosthetic valve failure
(ie, stenosis, regurgitation, or combined) was evaluated
according to the criteria of the American Society of
Echocardiography.18 Patients with at least a moderate degree
of both stenosis and regurgitation were included in the com-
bined group. Other patients were categorized according to
the primary mechanism of failure, either in the stenosis
group or in the regurgitation group. Body surface area was
calculated using the Mosteller formula. Internal diameter of
a surgical valve was derived from its label size and manufac-
turer charts.19 In cases for which label size was unknown,
internal diameter was defined according to available imaging
modes, such as computed tomography or transesophageal
echocardiography. Major clinical end points were assessed
according to the Valve Academic Research Consortium
criteria.20 Early postimplantation hemodynamic data were
obtained from either intraprocedural or first postprocedural
echocardiogram. Post–valve-in-valve severe prosthetic-
patient mismatch (PPM) was defined in cases that had a
postprocedure effective aortic orifice area divided by body
surface area of less than 0.65 cm2/m2.21
Statistical Analysis
Results are presented as mean (standard deviation) for con-
tinuous variables with normal distribution, asmedian (inter-
quartile range) for continuous variables without normal dis-
tribution, andasnumber (percentage) for categoricaldata.The
t test was used to compare normally distributed continuous
variables between the devices used during the valve-in-valve
procedure and theWilcoxon rank sum test was used for vari-
ables not normally distributed. One-way analysis of variance
was used to compare the stenosis, regurgitation, and com-
binedgroups fornormallydistributedcontinuousvariablesand
the Kruskal-Wallis test was used for non–normally distrib-
uteddata. The χ2 andFisher exact testswere used to compare
categorical variables. Time-to-event curvesusing theKaplan-
Meiermethodwere calculated. Results were compared using
the log-rank statistic.Highpostprocedural gradientswerede-
fined as those havingmean gradients of at least 20mmHg.20
Variables entered into bivariable models included sex, age,
baselineechocardiographicparameters (ie, leftventricularejec-
tion fraction), STS score, baseline renal failure, bioprosthetic
type (stented vs stentless) and size, device used during the
valve-in-valveprocedure,andproceduralaccess.Threesemipa-
rametric Cox proportional hazards regression analyses were
conducted.Thefirstwasanoverall analysisandtheotherswere
time-segmented analyses. For the latter, the hazard function
wasused as a guide to determine approximate timepoints for
the end of the early phase of hazard and the beginning of the
late phase. This occurred at approximately 30 days. There-
fore, piece-wise time-segmented Cox analyses were per-
formed for 2 periods. For one pair of analyses, deaths occur-
ringwithin the first 30postoperativedayswere analyzed,with
follow-up beyond that time set to 30 days; then deaths be-
yond 30 days were analyzed. Characteristics included in the
multivariablemodel for 1-year deathwere bioprosthesis label
size, mechanism of failure, procedural access, and STS score.
The results of themultivariable analysis are presented as haz-
ard ratios (HRs) for 1-year mortality with 95% confidence in-
tervals. A 2-sided P<.05 was considered statistically signifi-
cant.Statistical analysiswasperformedusingSPSSversion20.0
statistical software (IBM SPSS Inc).
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Results
Patient Demographics
Table 1 shows clinical characteristics of the 459 patients in-
cluded in the registry.Meanagewas 77.6 (SD, 9.8) years (range,
25-92 years) and 56% were men. The mechanism of failure of
surgical bioprostheseswas stenosis in 181patients (39.4%), re-
gurgitation in 139 (30.3%), and combined in 139 (30.3%). The
balloon-expandabledevicewasusedin246patients (53.6%)and
the self-expandable in 213 patients (46.4%). The distribution
offailuremodedifferedbetweentheballoon-expandabledevice
group (stenosis, n = 106 [43.1%]; regurgitation, n = 61 [24.8%];
combined,n = 79[32.1%])andtheself-expandabledevicegroup
(stenosis, n = 75 [35.2%]; regurgitation, n = 78 [36.6%]; com-
bined,n = 60 [28.2%]), asmore regurgitantbioprostheseswere
treatedbyself-expandabledevice implantation (P = .02).There
wereno significantdifferences in surgical risk scoreswhenpa-
tients were stratified according tomechanism of failure or ac-
cording to the device used during the valve-in-valve proce-
dure. The stenosis grouphadmorewomen andhigher patient
bodyweight, bodymass index, andbody surface area levels in
comparison with the other groups (Table 1).
Degenerated Bioprosthetic Valves and Characteristics
of Valve-in-Valve Procedures
Patients included in the registryhad1 to4previouscardiac sur-
geries (Table 2 andeTable 2 in the Supplement). Surgical valve
sizes were characterized as small (label size ≤21 mm; n = 133
[29%]), intermediate (>21 mm and <25 mm; n = 176 [38.3%]),
large (≥25mm;n = 139 [30.3%]), andunknown (n = 11 [2.4%]).
Bioprostheses were either stented (n = 366 [79.7%]) or stent-
less (n = 93 [20.3%]). The stenosis group had more stented
valves (95.6% vs 60.4% in the regurgitation group and 78.4%
in the combined group; P < .001) andmore small valves (37%
vs 20.9%and26.6%, respectively;P = .005). Therewasno sig-
nificant difference between the self-expandable andballoon-
expandable device groups in the rate of valve-in-valve proce-
dures performed in small bioprostheses (31.9% vs 26.4%,
respectively; P = .19).
Devices used included balloon-expandable 20-mm, 23-
mm, 26-mm, and 29-mm sizes (58.9% SAPIEN XT) and self-
expandable 23-mm,26-mm,29-mm,and31-mmsizes. eTable3
in the Supplement shows data on valve-in-valve procedural
characteristics. Device delivery access included transfemoral
(n = 270 [58.8%]), transapical (n = 171 [37.3%]), transaxillary
(n = 13 [2.8%]), and direct aortic (n = 5 [1.1%]). The main ac-
Table 1. Baseline Characteristics at the Time of Valve-in-Valve Procedure
Characteristics
All
(n = 459)
Mechanism of Surgical Valve Failure Device Used
Stenosis
(n = 181)
Regurgitation
(n = 139)
Combined
(n = 139) P Value
Self-
Expandable
(n = 213)
Balloon-
Expandable
(n = 246) P Value
Age, mean (SD), y 77.6 (9.8) 78.8 (7.8) 77.1 (10.6) 76.6 (11.1) .10 77.6 (10) 77.6 (9.7) .95
Men, No. (%) 257 (56) 87 (48) 93 (66.9) 77 (55.4) .002 113 (53.1) 144 (58.5) .25
Height, mean (SD), cm 167.2 (9.8) 167.1 (9.9) 168.1 (9.7) 166.5 (9.8) .20 166.9 (10) 167.4 (9.7) .59
Weight, mean (SD), kg 73.9 (15.2) 77.6 (16.5) 72 (13.3) 70.8 (14.1) <.001 73.7 (15) 74 (15.4) .84
BMI, mean (SD)a 26.4 (4.8) 27.7 (4.8) 25.4 (3.9) 25.5 (4.2) <.001 26.4 (4.6) 26.3 (4.4) .78
BSA, mean (SD), m2 1.85 (0.22) 1.89 (0.24) 1.83 (0.2) 1.8 (0.21) .002 1.84 (0.22) 1.85 (0.23) .76
LogEuroSCORE,
median (IQR), %b
29
(19.1-42.3)
29.8
(20-39.9)
25.7
(16-41.9)
30.3
(22.3-44.7)
.18 29
(18.6-38.7)
29
(19.3-44.2)
.48
STS score,
median (IQR), %b
10
(6.2-16.1)
9.9
(6.1-13.9)
9.9
(5.8-15.6)
10.8
(7.1-18.4)
.33 11
(6.2-17.3)
9.3
(6.1-14.1)
.13
Diabetes mellitus, No. (%) 125 (28.7) 69 (40.1) 28 (21.2) 28 (21.4) .001 62 (31.1) 63 (26.5) .29
Peripheral vascular disease,
No. (%)
114 (26.1) 53 (30.6) 31 (23.5) 30 (22.9) .22 37 (17.4) 77 (31.3) <.001
Chronic renal failure,
No. (%)c
224 (48.8) 80 (44.2) 71 (51.1) 72 (51.8) .37 81 (38) 140 (56.9) <.001
Previous stroke/TIA,
No. (%)
51 (11.7) 23 (13.3) 17 (12.8) 12 (9.2) .52 24 (12.2) 27 (11.3) .76
>1 Previous SAVR, No. (%) 62 (13.5) 16 (8.8) 23 (16.5) 23 (16.5) .06 27 (12.7) 35 (14.2) .63
NYHA functional class,
No. (%)
II 35 (7.8) 14 (7.7) 10 (7.2) 11 (7.9) .97 15 (7) 20 (8.1) .66
III 283 (61.9) 130 (71.8) 78 (56.1) 75 (54) .001 124 (58.2) 159 (64.6) .16
IV 141 (30.3) 37 (26.2) 51 (36.7) 53 (38.1) .001 74 (34.7) 67 (27.2) .08
Left ventricular ejection
fraction, mean (SD), %
50.3 (13.1) 51.7 (12.9) 49.0 (13.1) 49.7 (13.3) .16 49.1 (13.4) 51.2 (12.8) .08
Abbreviations: BMI, Bodymass index; BSA, body surface area; IQR, interquartile
range; NYHA, New York Heart Association; SAVR, surgical aortic valve
replacement; STS, Society of Thoracic Surgeons; TIA, transient ischemic attack.
a Bodymass index is calculated as weight in kilograms divided by height in
meters squared.
b Prediction of operative mortality after conventional surgical valve
replacement (STS score: http://riskcalc.sts.org/de.aspx; LogEuroSCORE:
http://www.euroscore.org/calcold.html). Range of scores is 0% to 100%;
higher score indicates greater patient risk.
c Calculated glomerular filtration rate <60mL/min.
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cess route in the self-expandabledevicegroupwas transfemo-
ral (n = 197 [92.5%]) while in the majority of the balloon-
expandable device group was transapical (n = 171 [69.5%];
P < .001). Device retrieval was attempted in 10.3% of self-
expandableprocedures.Asecondtranscatheterdevicewas im-
planted in 5.7%of the total patients (self-expandable, 7.5%vs
balloon-expandable, 4.1%; P = .05). Ostial coronary obstruc-
tion followingvalve-in-valve implantationoccurred in 2%and
was more frequent in the stenosis group (3.9%; P = .02).
Clinical Outcomes
Themedian duration of hospital stay after the procedurewas
8 days (interquartile range, 5-12 days). At 30 days, 35 patients
(7.6%) had died. Table 3 includes data on procedural out-
comes.Patients in the stenosis grouphadahigher 30-daymor-
tality rate (10.5% vs 4.3% in the regurgitation group and 7.2%
in the combinedgroup;P = .04). Therewerenodifferencesbe-
tween the self-expandable and balloon-expandable device
groups in terms of mortality or stroke rates. The balloon-
expandable device group had more major/life-threatening
bleeding andmore acute kidney injury events, while the self-
expandabledevicegrouphadmorepermanentpacemaker im-
plantation.Aortic regurgitationofat leastmoderatedegreewas
evident in 25 cases (5.4%) after valve-in-valve procedure and
was more common in the regurgitation group (9.4% vs 2.8%
in the stenosis group and 5% in the combined group; P = .04)
and in the self-expandable device group (8.9% vs 2.4% in the
balloon-expandable device group; P = .002).
The degree of postprocedure residual aortic stenosis was
higher in the stenosis group, manifested by lower mean ori-
fice area and higher mean gradient (orifice area, 1.37 [SD,
0.33] cm2 and mean gradient, 18.5 [SD, 9.8] mm Hg vs 1.56
[SD, 0.51] cm2 and 12 [SD, 6.7] mm Hg in the regurgitation
group and 1.56 [SD, 0.65] cm2 and 16.1 [SD, 8.3] mmHg in the
combined group, respectively; P < .001 for each compari-
son). Postprocedural gradients were assessed in 429
patients. Moderately elevated postprocedural gradients
(mean gradients ≥20 mm Hg) were recorded in 115 patients
(26.8%) (eFigure 2 in the Supplement). Elevated postproce-
dural gradients were more common with balloon-
expandable devices in comparison with self-expandable
devices (HR, 1.87; 95% CI, 1.21-2.9; P = .005); for small surgi-
cal valves, 41.2% vs 23.4% (P = .04) and for intermediate-
sized valves, 35.8% vs 19.4% (P = .01), respectively. Severe
PPM occurred in 31.8% of patients surviving aortic valve-in-
valve procedure. The incidence of severe PPM was lower in
patients with predominantly bioprosthesis regurgitation at
baseline (19.3% vs 36.1% and 36.4% in those with predomi-
nant stenosis and combined failure, respectively; P = .03)
and higher in patients who received a balloon-expandable
device vs a self-expandable device (43.8% vs 15.2%, respec-
tively; P < .001). One-year survival was not affected by hav-
ing severe PPM (86.7% [95% CI, 77.6%-95.8%] vs 89.1% [95%
CI, 82.2%-96%] in patients without severe PPM; P = .69).
Time-to-event curves are depicted in Figure 1. No pa-
tients were lost to follow-up. Median follow-up time was 301
Table 2. Surgical Valve Characteristics at the Time of Valve-in-Valve Procedure
Characteristics
All
(n = 459)
Mechanism of Surgical Valve Failure Device Used
Stenosis
(n = 181)
Regurgitation
(n = 139)
Combined
(n = 139) P Value
Self-
Expandable
(n = 213)
Balloon-
Expandable
(n = 246) P Value
Time since last SAVR, median
(IQR), ya
9 (6-12) 8 (5-11) 10(7-14) 10 (7-14) .04 9 (7-13) 9 (6-12) .08
Type, No. (%) <.001 <.001
Stented 366 (79.7) 173 (95.6) 84 (60.4) 109 (78.4) 152 (71.4) 214 (87)
Stentless 93 (20.3) 8 (4.4) 55 (29.6) 30 (21.6) 61 (28.6) 32 (13)
Label size, No. (%)
≤21 mm 133 (29) 67 (37) 29 (20.9) 37 (26.6) .005 68 (31.9) 65 (26.4) .19
>21 mm and <25 mm 176 (38.3) 74 (40.9) 43 (30.9) 59 (42.4) .09 83 (39) 93 (37.8) .80
≥25 mm 139 (30.3) 34 (18.8) 65 (46.8) 40 (28.8) <.001 53 (24.9) 86 (35) .02
Unknown 11 (2.4) 6 (3.3) 2 (1.4) 3 (2.2) .54 9 (4.2) 2 (0.8) .02
Internal diameter, No. (%)
<20 mm 126 (27.5) 53 (29.3) 32 (23) 41 (41.7) .37 66 (31) 60 (24.4) .11
≥20 mm and <23 mm 230 (50.1) 102 (56.4) 64 (34.5) 64 (46) .10 100 (46.5) 130 (52.8) .21
≥23 mm 103 (22.4) 26 (14.4) 43 (30.9) 34 (24.5) .002 46 (21.6) 57 (23.2) .69
AV area, mean (SD), cm2 0.95 (0.48) 0.69 (0.21) 1.48 (0.6) 0.91 (0.31) <.001 0.99 (0.49) 0.91 (0.46) .04
AV index, mean (SD), cm2/m2b 0.51 (0.28) 0.38(0.13) 0.83 (0.37) 0.51(0.19) <.001 0.55 (0.31) 0.49 (0.25) .05
AV maximum gradient, mean
(SD), mm Hg
60.8 (27.4) 75.2 (23.1) 34.3 (17.7) 64.6 (22.8) <.001 59.7 (27.2) 61.8 (27.6) .44
AV gradient, mean (SD), mm Hg 36.2 (18.4) 46.4 (16.1) 18.0 (10.1) 37.6 (14.9) <.001 35 (18.5) 37.3 (18.3) .21
AV regurgitation of at least
moderate degree, No. (%)c
296 (64.5) 22 (12.2) 139 (100) 135 (97.1) <.001 143 (67.1) 153 (63) .27
Abbreviations: AV, aortic valve; IQR, interquartile range; SAVR, surgical aortic
valve replacement.
a Time interval between last SAVR and valve-in-valve procedure.
bAV index = AV area (cm2)/patient body surface area (m2).
c Evaluated according to the criteria of the American Society of
Echocardiography.18
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days (interquartile range, 53-504days). Overall 1-yearKaplan-
Meier survival ratewas83.2% (95%CI, 80.8%-84.7%;62death
events; 228survivors). Patients in thestenosisgrouphadworse
1-year survival (76.6%;95%CI, 68.9%-83.1%;34deaths;86 sur-
vivors) vs the regurgitation group (91.2%; 95% CI, 85.7%-
96.7%;10deaths;76survivors)andthecombinedgroup(83.9%;
95% CI, 76.8%-91%; 18 deaths, 66 survivors) (P = .01). Simi-
larly, patients with small valves had worse 1-year survival af-
ter valve-in-valve procedure (74.8%;95%CI, 66.2%-83.4%; 27
deaths; 57 survivors) vswith intermediate-sizedvalves (81.8%;
95% CI, 75.3%-88.3%; 26 deaths; 92 survivors) or with large
valves (93.3%; 95% CI, 85.7%-96.7%; 7 deaths; 73 survivors)
(P = .001) (Figure 1, A and B). There was no significant differ-
ence in survival between patients undergoing self-
expandable and balloon-expandable valve-in-valve proce-
dures (Figure 1C). One-year mortality was higher among
patients undergoing transapical procedures, those with STS
scores higher than 20%, and those with a baseline left ven-
tricular ejection fraction of less than 45% (eFigures 3-8 in the
Supplement).
Figure 2 includes data on correlates formortalitywithin 1
year after valve-in-valve procedures. Independent correlates
included small surgical bioprostheses (HR, 2.04; 95%CI, 1.14-
3.67; P = .02), baseline surgical bioprosthesis stenosis (vs re-
Table 3. Clinical Outcomes
Outcomes
All
(n = 459)
Mechanism of Surgical Valve Failure, No. (%) Device Used, No. (%)
Stenosis
(n = 181)
Regurgitation
(n = 139)
Combined
(n = 139) P Value
Self-
Expandable
(n = 213)
Balloon-
Expandable
(n = 246) P Value
Duration of hospital stay,
median (IQR), d
8 (5-12) 7 (5-11) 7 (5-12) 8 (6-13) .21 7 (5-12) 8 (6-13) .07
Thirty-day outcomes
Death, No. (%) 35 (7.6) 19 (10.5) 6 (4.3) 10 (7.2) .04 15 (7) 20 (8.1) .66
Cardiovascular death, No. (%) 30 (6.5) 16 (8.8) 5 (3.6) 9 (6.5) .06 12 (5.6) 18 (7.3) .47
NYHA functional class,
No. (%)
I/II 313 (92.6) 126 (91.3) 100 (94.3) 87 (92.6) .83 160 (93) 153 (93.3) .94
III/IV 25 (7.4) 12 (8.7) 6 (5.7) 7 (7.4) .83 12 (7) 13 (7.8) .94
Major stroke, No. (%)a 8 (1.7) 1 (0.6) 3 (2.2) 4 (2.9) .26 2 (0.9) 6 (2.4) .22
Death or major stroke,
No. (%)
42 (9.2) 19 (10.5) 9 (6.5) 14 (10.1) .42 17 (8) 25 (10.2) .22
Major vascular complication,
No. (%)a
42 (9.2) 14 (7.7) 10 (7.2) 18 (12.9) .11 16 (7.5) 26(10.6) .26
Major/life-threatening
bleeding, No. (%)a
37 (8.1) 20 (11) 5 (3.6) 12 (8.6) .01 10 (4.7) 27 (11) .01
Acute kidney injury type II/III,
No. (%)a
34 (7.4) 16 (8.8) 10 (7.2) 8 (5.8) .58 9 (4.2) 25 (10.2) .02
Permanent pacemaker
implantation, No. (%)
38 (8.3) 17 (9.4) 12 (8.6) 9 (6.5) .63 26 (12.2) 12 (4.9) .005
AV area, mean (SD), cm2 1.47 (0.5) 1.37 (0.33) 1.56 (0.51) 1.56 (0.65) .01 1.58 (0.41) 1.38 (0.54) .001
AV index, mean (SD),
cm2/m2b
0.77 (0.25) 0.71 (0.15) 0.82 (0.23) 0.84 (0.35) .004 0.83 (0.19) 0.74 (0.28) .004
AV maximal gradient,
mean (SD), mm Hg
28.3 (14.1) 32.2 (14.7) 22.4 (11.6) 29.1 (13.6) <.001 26.2 (12.1) 30.3 (15.4) .002
AV mean gradient,
mean (SD), mm Hg
15.8 (8.9) 18.5 (9.8) 12 (6.7) 16.1 (8.3) <.001 14.1 (7.3) 17.2 (9.7) <.001
AV regurgitation of at least
moderate degree, No. (%)c
25 (5.4) 5 (2.8) 13 (9.4) 7 (5) .04 19 (8.9) 6 (2.4) .002
Left ventricular ejection
fraction, mean (SD), %
51.6 (11.5) 53.7 (9.9) 48.9 (11.6) 51.2 (12.9) .002 51.2 (12.2) 51.7 (10.8) .66
One-year outcomes
Death, No. (%) 62 (16.8) 34 (23.4) 10 (8.8) 18 (16.1) .01 25 (15) 37 (18.7) .44
NYHA functional class,
No. (%)
I/II 163 (86.2) 62 (84.9) 46 (85.2) 55 (88.7) .34 88 (81.6) 75 (82.4) .89
III/IV 26 (13.8) 11 (15.1) 8 (14.8) 7 (11.3) .34 10 (18.4) 16 (17.6) .89
AV area, mean (SD), cm2 1.38 (0.42) 1.28 (0.29) 1.51 (0.48) 1.36 (0.45) .01 1.55 (0.41) 1.29 (0.39) .006
AV maximal gradient,
mean (SD), mm Hg
30 (14.7) 32.3 (14.9) 25.2 (15.4) 32.1 (12.5) .005 25.3 (11.9) 33.3 (16) <.001
AV mean gradient,
mean (SD), mm Hg
16.9 (9.1) 18.3 (9.5) 13.8 (8.9) 18.4 (8) .001 13.5 (7) 19.4 (9.6) <.001
Abbreviations: AV, aortic valve; IQR, interquartile range; NYHA, New York Heart
Association.
a According to the Valve Academic Research Consortium definition.
bAV index = AV area (cm2)/patient body surface area (m2).
c Evaluated according to the criteria of the American Society of
Echocardiography.18
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gurgitation;HR, 3.07; 95%CI, 1.33-7.08;P = .008), transapical
access (HR, 2.25; 95% CI, 1.26-4.02; P = .006), and STS score
(per 1% increment; HR, 1.01; 95% CI, 1.00-1.01; P < .001). In-
dependent correlates for early mortality (≤30 days) included
small surgical bioprostheses (HR, 2.25; 95% CI, 1.03-4.93;
P = .04) and for latemortality (>30days) includedbaseline sur-
gical bioprosthesis stenosis (HR, 3.33; 95% CI, 1.00-11.31;
P = .05).
Discussion
The VIVID Registry is a multinational comprehensive evalu-
ation of transcatheter valve implantations for failed surgical
aortic bioprostheses. Survival after valve-in-valve proce-
dureswas associatedwith surgical valve size andmechanism
of failure. Patientswithbaseline stenosis and thosewith small
surgical valves had worse clinical outcomes after valve-in-
valve procedures.
Mechanism of Failure of Bioprosthetic Valves
and Valve-in-Valve Procedures
Valve-in-valve implantation should be considered a hetero-
geneousgroupofprocedures,performed inwidelydiverse sur-
gical valveswithdifferent degenerationmodes.22 Bioprosthe-
sis failuremaypresentas stenosis thatoccursasaconsequence
of calcification, pannus, or, less commonly, thrombosis. Fail-
ure may also present as regurgitation secondary to wear and
tear or infection.23,24 The mode of failure in the VIVID regis-
trywas relativelybalancedamong stenosis, regurgitation, and
acombinationofboth.Although therewasnodifference inpa-
tient age or calculated risk scores among the groups, clinical
outcomes differed significantly. Higher mortality in the ste-
nosis groupcouldpartially be attributed tohigher rates of spe-
cific life-threatening procedural complications, such as ostial
leftmainobstruction.Nevertheless, long-termdissimilaritybe-
tween the groups could be a result of differences in baseline
characteristicsandpostproceduralhemodynamics.Aftervalve-
in-valve implantation, patients with baseline stenosis had a
lower valve area andhigher gradients. Prosthetic-patientmis-
match occurs when the effective orifice area is physiologi-
cally too small in relation to patient body size.21 In the cur-
rent analysis, patients with predominantly surgical valve
stenosis had larger body size measures (body weight, body
mass index, and body surface area); nevertheless, they had
smaller surgical valves implanted compared with the other
groups. In patients undergoing surgical aortic valve replace-
ment, lower effective orifice area in relation to body size is as-
sociated with lower left ventricular mass regression, less re-
covery in ventricular systolic function, and lower long-term
survival.21,25-28
Evaluation of Patients for Valve-in-Valve Procedures
Thorough assessment of candidates for valve-in-valve
implantation is a key step to obtain optimal results.22 The
current analysis highlights the need for meticulous evalua-
tion of bioprosthesis mechanism of failure before attempt-
ing a valve-in-valve procedure. Patients who are diagnosed
as having failed surgical valves secondary to stenosis should
be further separated into those with degenerated valves and
those who have elevated gradients and small effective ori-
fice area as a result of severe PPM with their surgical valve.
Occasionally, it is clinically difficult to differentiate between
Figure 1. Time-to-Event Curves in Patients Undergoing Valve-in-Valve
Procedures
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a Surgical valve sizes were as follows: small, label size21 mm; intermediate,
>21 mm and <25mm; and large,25mm. In 11 patients (2.4%), label size was
unknown.
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those entities, and a patient may have a combination of
both. Small bioprostheses (label size ≤21 mm) have small
effective orifice areas and the gradients across them are
commonly high, even in the absence of structural degenera-
tion, such as impaired leaflet mobility, significant calcifica-
tion, or pannus.29 Therefore, markers for stenosis in bio-
prostheses should lead to a more detailed assessment of
previous echocardiographic examinations and changes in
clinical status over years. It seems that the valve-in-valve
approach should only be rarely offered to patients after
implantation of small surgical valves without signs of valve
degeneration, for which gradients are relatively stable over
time.
Candidates with surgical valve regurgitation should be
evaluated for the location of the leak. Significant paravalvu-
lar leak should not be treated by valve-in-valve implantation
since no considerable change is expected in regurgitation
severity.22 The current registry reveals an elevated rate of re-
sidual leak in the group of patients with baseline regurgita-
tion (9.4%) in comparison with patients with predominantly
stenosis (2.8%). Significantpostprocedural regurgitationcould
be attributed to improper treatmentof patientswithpredomi-
nantly paravalvular leak at baseline. Transesophageal echo-
cardiography is a keymodeduring this screening process and
should be routinely performed for evaluating leak origin.
Implications for Cardiac Surgery
Increasing global valve-in-valve experience may affect car-
diac surgery practice. The valve-in-valve approach may offer
an effective, less invasive treatment for patients with failed
surgical bioprostheses and, therefore, the trend toward
implantation of bioprostheses in younger patients is
expected to grow.1 It is difficult to define an optimal cutoff
age for bioprostheses implantation rather than mechanical
valves.30 However, surgeons should be aware that their tech-
nique is crucial to allow for the possibility of successful
valve-in-valve implantation when bioprosthesis failure
occurs years later. According to the VIVID Registry analysis,
valve-in-valve outcomes are worse in patients with small
surgical valves (label size ≤21 mm) and those with stenosis as
the mechanism of failure; an attempt to address these limi-
tations may possibly be made during the index procedure by
providing the largest effective orifice area achievable. How-
ever, annular enlargement and other related techniques
must balance the potential benefit of larger valve against
described increase in operative complications.31-33
Figure 2. Results ofMultivariable Analyses for Correlates for 1-YearMortality After Valve-in-Valve Implantation
P Value
101.00.1
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operative mortality after
conventional surgical valve
replacement (http://riskcalc.sts.org
/de.aspx).
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Limitations
The valve-in-valve therapeutic approach represents a widely
diverse heterogeneous group of procedures; hence, it is diffi-
cult to stratify patients according to each type of the numer-
ous surgical valves treated. Nevertheless, stratification ac-
cording tomechanismof failureandbioprosthesessizeshowed
amajor influenceonclinical outcomesafter valve-in-valve im-
plantation. Since specific label sizes of surgical valves such as
the 19mmwere not common (2.4%), wewere not powered to
comparedifferent surgical valve sizeswithout clustering cases
into subgroups. Nevertheless, dividing surgical bioprosthe-
ses into small, intermediate, and large valve sizes, in accor-
dancewithprevious reports, is clinically relevant and showed
clinical significance when defining small valve size as those
having a label size of 21 mm or smaller.34,35
Study results reveal that PPMof the implanted transcath-
eter heart valve device during valve-in-valve procedures did
not influence 1-year survival. However, analyses were lim-
ited by lack of echocardiographic data immediately after sur-
gical implantation (median of 9 years before the valve-in-
valve procedure) that would have enabled evaluation of PPM
of the implanted surgical valve. Therefore, a clear differentia-
tion between degeneration of the surgical bioprosthesis and
PPM is challenging.
Although dozens of baseline medical and echocardio-
graphic parameters were included in the analyses (Table 1,
Table 2, and Table 3 and eTables 2 and 3 in the Supplement),
analyses is limited by lack of several parameters known to be
related to clinical outcomes in patients with structural aortic
valve disease, including left ventricularmass index, diastolic
function, ischemic cardiomyopathy, and frailty.
Conclusions
In this registryofpatientswhounderwent transcathetervalve-
in-valve implantation for degenerated bioprosthetic aortic
valves, overall 1-year survival was 83.2%. Survival was lower
among patientswith small bioprostheses and thosewith pre-
dominant surgical valve stenosis.
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